Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.

Authors :: Leary A
Estévez-García P
Sabatier R
Ray-Coquard I
Romeo M
Barretina-Ginesta P
Gil-Martin M
Garralda E
Bosch-Barrera J
Morán T
Martin-Martorell P
Nadal E
Gascón P
Rodon J
Lizcano JM
Muñoz-Guardiola P
Fierro-Durán G
Pedrós-Gámez O
Pérez-Montoyo H
Yeste-Velasco M
Cortal M
Pérez-Campos A
Alfon J
Domenech C
Pérez-Fidalgo A
Oaknin A
Source :: BMC cancer [BMC Cancer] 2024 Jul 29; Vol. 24 (1), pp. 911. Date of Electronic Publication: 2024 Jul 29.
Publication Year :: 2024

Full Text Access

Tools